에 대한 최신 뉴스 Herc Holdings (NYSE:HRI) 주식

Herc Hldgs

Herc Holdings Inc is an equipment rental company that was spun out of Hertz Global in 2016. It is currently the equipment rental company (4% market share) in North America, after United Rentals and Sunbelt Rentals, with a fleet size of $6.4 billion. It serves commercial and residential construction customers, the environmental sector, industrial entities, and entertainment production companies. During much of its 50-year-plus history, the company has rented equipment such as aerial lifts to its customers for intermittent use. More recently, it has broadened its catalog to include a host of specialty items. Separately, Herc Holdings' prepares now to incorporate long-term rentals to industrial customers where Herc maintains its own staff at the customer site.

Mid Cap

News

Movers

Trading Ideas

$BTC

IBRX

IONQ

IRTC

WULF

이들 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 이뮤니티바이오(NASDAQ:IBRX)의 주식은 회사가 재발성 B-세포 비호지킨 림프종에 대한 CAR-NK 세포 치료제의 1상 임상 연구에서 첫 환자에게 투여했다고 발표한 후 49.86% 상승했다.

트럼프 미디어와 스트라이드는 지난주 최고 성과를 보여준 10개 중형주 중 일부 (10월 21일-10월 25일)

Herc Holdings Inc

Horiba Ltd

Most people assume that crypto's most popular financial instruments are tokens, but index funds are gaining significant traction. In traditional finance (TradFi), index-based funds have historically outperformed single-asset funds in terms of assets under management (AUM), providing investors with diversified exposure while mitigating risk.
While crypto ETFs, particularly <a href="https://www.sec.gov/newsroom/speeches-statements/gensler-statement-spot-bitcoin-011023">Bitcoin ETFs approved by the Securities and Exchange Commission (SEC) in January 2024</a>, have dominated recent market discussions, index funds offer a broader approach to digital asset investing. Instead of relying on the performance of a single asset, index funds track baskets of assets, creating the diversification that investors have long favored in traditional markets. 
In crypto, this approach holds similar potential. Instead of focusing on a single token like Bitcoin or Ethereum, index funds track multiple high-performing digital assets, offering exposure to the broader market while reducing concentration risk. The Bitwise 10 Crypto Index Fund was one of the first such crypto indexes, launched in 2017, and Fidelity and Bloomberg soon followed with its Bloomberg Galaxy Crypto Index in 2018.
As institutional adoption grows, multi-token index funds that take their unique approach to tracking, benchmarking, and reflecting the overall crypto sector could play a key role in bridging traditional investment strategies with the digital asset space.
<h2 class="wp-block-heading">Indexes spare the hassle &#8211; and risk &#8211; of investing in individual coins</h2>
The abundance of information about a coin &#8211; spread across white papers, discussion boards, social media platforms, and messaging apps &#8211; is difficult to keep up with for one coin, let alone the 1000s of digital assets at any given time. While ETFs save investors the inconvenience of buying, storing, and securing $BTC or other coins with forthcoming ETFs, investors must keep up with this real-time information firehose to manage their portfolios.
When there are many ETFs on the market, investors need to sift through piles of information before deciding which one to ultimately purchase. This is burdensome for most retail investors who simply want some exposure to crypto without getting into the technical details.&nbsp;
From this viewpoint, crypto indexes are a much better option: Investors can defer to the collective growth of a handful of top coins, eliminating the need to perform constant, extensive research on any one coin or ETF.
<h2 class="wp-block-heading">Indexes alleviate users from having to trade short-term </h2>
When investing stocks, short-term trading is often necessary. For instance, if you held shares of Nvidia ($NVDA), you might have felt compelled to buy or sell after the stock dropped following the Deepseek announcement.
In contrast, if you are an investor in the S&amp;P 500, which includes $NVDA, you would not need to respond to any market news. You could buy shares in the S&amp;P 500 and count on the overall growth of the market to withstand any changes to a single stock. Such investors can rest easy, knowing that their investment will always be bullish in the long-term (the S&amp;P boasts an average annual return of over <a href="https://www.investopedia.com/ask/answers/042415/what-average-annual-return-sp-500.asp">10% going back to 1957</a>).
Crypto indexes will be attractive in the same way. Instead of having to regularly take action on a specific token position, investors can simply buy shares in a crypto index and leave them untouched for the long-term. In the parlance of the crypto community, they can "hodl." Such investors can count on the continued growth of crypto to take their shares to new heights over time.
<h2 class="wp-block-heading">Indexes protect investors from the risks associated with FOMO </h2>
The fear of missing out (FOMO) is a real problem in crypto. When investors sit on the sidelines and see peers make money from different financial instruments, they may be prone to jump in and make ill-advised decisions.
FOMO is rampant now with meme coins, which Solana has made easier to launch than ever. A few cycles ago, there was also FOMO for non-fungible tokens and even play-and-earn tokens. All of these instruments are highly volatile. For example, the $SQUID token plummeted 99% in <a href="https://www.bbc.com/news/business-59129466">value in a matter of minutes</a>, while once popular NFT collections, <a href="https://www.theguardian.com/sport/2025/jan/14/almost-10000-images-of-tennis-balls-plunge-up-to-90-in-value-as-australian-open-appears-to-ditch-nfts?utm_source=chatgpt.com">such as those of tennis balls by the Australian Open</a>, were down by 90%.&nbsp;
Indexes can prevent investors from risky FOMO-based decision-making because they already have broad exposure. For example, they would not need to invest in meme coins because most popular indexes include Solana, the preferred blockchain for such assets. Similarly, they would not need to purchase any single NFTs because indexes always have Ethereum, the market leading blockchain for them.&nbsp;
Indexes will likewise give investors exposure to other major trends in the future, all without having to buy into individual assets that are highly risky on their own.
<h2 class="wp-block-heading">Indexing your Crypto Exposure&nbsp;</h2>
As crypto investment vehicles evolve, indexes represent the next logical step in providing retail investors with diversified, low-maintenance exposure to the market. While ETFs solve the challenge of buying and storing individual tokens, they still require investors to stay informed about specific assets. Indexes, on the other hand, simplify the investment process by spreading risk across multiple top-performing cryptocurrencies, much like how traditional stock indexes provide long-term stability.
By mitigating the risks of short-term trading and FOMO-driven decisions, indexes offer a more resilient approach to crypto investing. Whether the market shifts toward new trends or faces periods of volatility, indexes allow investors to participate in crypto's overall growth without the burden of constant research and rebalancing. Just as stock indexes have become a cornerstone of traditional investing, crypto indexes are poised to become a preferred vehicle for long-term, diversified exposure to the digital asset space.&nbsp;
Crypto, in short, operates like a book: The best guide is often the index.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

The Rise of Passive Investing: How Crypto is Evolving for Retail Investors

WIIM

Westlake shares are trading lower after the company reported worse-than-expected Q4 financial results.

Unity Software shares are trading lower. The company announced a $500 million convertible senior note offering.

A. Preview of timsTOF Ultra 2 system with novel Athena Ion Processor (AIP):
- Improves protein group identification in single-cell proteomics (SCP) by 15%-20%, and peptide identifications in SCP by 20%-25%
-Advances immunopeptidomics with 15%-20% more immunopeptide identifications
B. Launch of DeutEx&#x2122; software for hydrogen-deuterium exchange (HDX-MS) analysis
C. OmniScape&#x2122; 2025b: a breakthrough in top-down protein sequencing software
D. Advances in ProteoScape&#x2122; and Glycoproteomics software capabilities
E. Advances in TwinScape&#x2122; for cloud-based, AI-enabled proteomics quality monitoring

BRKR

Bruker Unveils 4D-Proteomics Breakthrough At US HUPO: Enhanced Single-Cell and Immunopeptidomics With timsTOF Ultra 2 And Athena Ion Processor

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $53 price target.

Price Target

Reiteration

Analyst Ratings

XENE

HC Wainwright & Co. Reiterates Buy on Xenon Pharmaceuticals, Maintains $53 Price Target

HC Wainwright &amp; Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) with a Buy and maintains $74 price target.

SWTX

HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target

MCHP

Microchip Technology Launched MPLAB XC Unified Compiler Licenses For Its MPLAB XC8, XC16, XC-DSC and XC32 C Compilers

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.laserphotonics.com%2F&amp;esheet=54212399&amp;newsitemid=20250224082074&amp;lan=en-US&amp;anchor=Laser+Photonics+Corporation&amp;index=1&amp;md5=223dc3d3ec3a60d49aba12f490f75c5b">Laser Photonics Corporation</a> (LPC) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>), a leading global developer of industrial laser systems for cleaning and other material processing applications, in partnership with its sibling company Fonon Technologies, announced today the receipt of a second order for its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fonon.us%2Fproducts%2Fdefensetech-mrls-portable-finishing-laser-1020&amp;esheet=54212399&amp;newsitemid=20250224082074&amp;lan=en-US&amp;anchor=DefenseTech+MRLS+Portable+Finishing+Laser&amp;index=3&amp;md5=223a07b9d89ac41eff38d88550ae268c">DefenseTech MRLS Portable Finishing Laser</a> (MF-1020) handheld cleaning system. This order was facilitated once again through their distribution partner, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fincrediblesupply.com%2F&amp;esheet=54212399&amp;newsitemid=20250224082074&amp;lan=en-US&amp;anchor=Incredible+Supply+%26amp%3B+Logistics&amp;index=4&amp;md5=d2db227391448095ee4cf287ffd15f20">Incredible Supply &amp; Logistics</a> (ISL), an award-winning product distribution and third-party logistics (3PL) company.
The DTMF-1020 air-cooled handheld pulsed laser cleaning system, equipped with dual-axis technology, streamlines maintenance processes. This system will be utilized by the same Navy command in Virginia Beach that ordered the first unit.

Government

Regulations

LASE

Laser Photonics Secures Second Order for DefenseTech MRLS Laser Cleaning System

Earnings

ATCH

Reported Earlier, AtlasClear Holdings Q2 EPS $(1.11) Down From $2.22 YoY, Sales $2.75M

SOAR

Volato Announced Today That It Has Begun Bitcoin Mining Operations, Marking An Early But Significant Step In Its Broader Exploration Of Aviation-integrated Cryptocurrency Mining

Leerink Partners analyst Mike Kratky initiates coverage on Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) with a Outperform rating and announces Price Target of $28.

Initiation

BBNX

Leerink Partners Initiates Coverage On Beta Bionics with Outperform Rating, Announces Price Target of $28

<ul>
<li>SYMBRAVO demonstrated statistically significantly greater migraine treatment response compared to prior treatment with an oral CGRP inhibitor (p&lt;0.001, mTOQ-4 total score, primary endpoint)</li>
<li>2-hour pain freedom for most attacks reported at least half the time by 47.9% of patients after SYMBRAVO versus 1.0% after oral CGRPs (p&lt;0.001)</li>
<li>24-hour or greater sustained pain relief after a single dose reported by 47.9% of patients after SYMBRAVO versus 16.7% after oral CGRPs (p&lt;0.001)</li>
<li>Ability to quickly return to normal activities reported by 51.0% of patients after SYMBRAVO versus 11.5% after oral CGRPs (p&lt;0.001)</li>
<li>SYMBRAVO improved quality of life compared to after oral CGRPs (p&lt;0.001, MSQ)</li>
</ul>

AXSM

Axsome Therapeutics Unveils SYMBRAVO Success In EMERGE Phase 3 Trial, Paving The Way For Enhanced Migraine Treatment For CGRP Inhibitor Non-Responders

PepGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1).
"These results far exceeded our expectations for splicing correction following a single dose of PGN-EDODM1. Mis-splicing is the underlying cause of DM1 pathology, and we believe the mean splicing correction observed at 28 days following a single dose of PGN-EDODM1 at 10 mg/kg in the FREEDOM clinical trial surpasses those reported to date in multi-dose clinical trials of up to nine months in duration in patients with DM1. We believe this is a strong indicator of our EDO technology's potential to deliver therapeutic oligonucleotides to the nucleus and PGN-EDODM1's potential to address the underlying cause of disease," said James McArthur, PhD, President and CEO of PepGen. "We believe these results provide initial validation of PGN-EDODM1's ability to selectively bind the pathogenic CUG-repeat DMPK RNA and we look forward to evaluating PGN-EDODM1 with more doses over longer time periods in our FREEDOM2-DM1 multiple ascending dose study. Based on these initial results, we aim to build on the significant correction of mis-splicing observed in this single-dose study to potentially provide improved functional benefit for patients who currently have no available approved therapeutic options."

PEPG

PepGen Reports Early Data From FREEDOM-DM1 Trial for Myotonic Dystrophy

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) with a Buy and maintains $190 price target.

BCPC

HC Wainwright & Co. Reiterates Buy on Balchem, Maintains $190 Price Target

B of A Securities analyst Peter Henderson maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Buy and raises the price target from $149 to $175.

B of A Securities Maintains Buy on Live Nation Entertainment, Raises Price Target to $175

Mr. Doogue's ascension to CEO comes after 27 years of rising through the leadership ranks at Allegro, during which time he enabled many of Allegro's disruptive technologies, originally as an engineer and later as a business leader. Immediately prior to this promotion, Mr. Doogue served as Allegro's Executive Vice President and its first Chief Technology Officer (CTO), leading technology development and worldwide operations, which includes manufacturing, procurement, and quality. Mr. Doogue also previously served as the Company's Senior Vice President of Technology and Products, which included direct oversight of each of the Company's business units. As a testament to his roots as an engineer and technology innovator, Mr. Doogue personally holds 75 semiconductor-related U.S. patents.

ALGM

Allegro MicroSystems Names Mike Doogue As Chief Executive Officer

B of A Securities analyst John Murphy downgrades Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) from Neutral to Underperform and lowers the price target from $13 to $10.

Downgrades

RIVN

B of A Securities Downgrades Rivian Automotive to Underperform, Lowers Price Target to $10

IVVD

Invivyd Says FDA Declined Its Request To Expand Existing Emergency Use Authorization Of PEMGARDA To Include Treatment Of Mild-to-moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and maintains $185 price target.

NBIX

HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $185 Price Target

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus (T1D).
&nbsp;
Rezpegaldesleukin is a novel agonistic T regulatory (Treg) cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional Treg cells and engaging multiple immunoregulatory pathways. Tregs are known to play a key role in the pathogenesis of T1D.1
Under the agreement, TrialNet will conduct the Phase 2 randomized, double-blind, placebo-controlled, clinical trial to investigate the safety and potential efficacy of rezpegaldesleukin in approximately 70 adults and children with new onset stage 3 T1D. Nektar will supply rezpegaldesleukin for the trial and will provide support for the study, including pharmacokinetic and other analyses. Nektar will retain all rights to the rezpegaldesleukin program under the collaboration.

NKTR

Nektar Therapeutics and TrialNet Partner to Study Rezpegaldesleukin for Type 1 Diabetes

Press Releases

Herc Holdings Inc. Declares Regular Quarterly Dividend of $0.665 Per Share

Herc Holdings Announces Date for Fourth Quarter and Full Year 2024 Earnings Call and Webcast

Herc Holdings Inc. Increases Quarterly Dividend by 5% to $0.70 Per Share

Herc Holdings to Participate in Barclays 42nd Annual Industrial Select Conference

Herc Holdings Reports Full Year 2024 Results and Announces 2025 Full Year Guidance

H&E Equipment Services, Inc. Receives Superior Proposal from Herc Holdings Inc.

Herc Holdings Confirms Superior Proposal to Acquire H&E Equipment Services

Herc Holdings and H&E Equipment Services Enter into Definitive Merger Agreement

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of H&E Equipment Services, Inc.

H&E Rentals Reports Fourth Quarter and Full Year 2024 Results

HEES

Applied Industrial Technologies, Inc. Common Stock

Applied Industrial Techs

Air Lease Corporation Class A Common Stock

Air Lease

Boise Cascade

Beacon Roofing Supply, Inc. - Common Stock

Beacon Roofing Supply

Core & Main

Dnow

Distribution Solutions Group, Inc. - Common Stock

Distribution Solns Gr

DXP Enterprises

Fastenal

Ferguson Enterprises

FTAI Aviation

GATX

W.W. Grainger

H&E Equipment Services, Inc. - Common Stock

H&E Equipment Servs

Herc Holdings

McGrath RentCorp

MSC Industrial Direct Company, Inc. Common Stock

MSC Industrial Direct Co

Rush Enterprises, Inc. - Class A Common Stock

Rush Enterprises

Rush Enterprises, Inc. - Class B Common Stock

SiteOne Landscape Supply, Inc. Common Stock

SiteOne Landscape Supply

United Rentals

WESCO Intl

Willis Lease Finance Corporation - Common Stock

Willis Lease Finance

Watsco

Xometry

Goldman Sachs

Barclays

JP Morgan

Baird

B of A Securities

이들 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 이뮤니티바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>)의 주식은 회사가 재발성 <a href="https://www.benzinga.com//node/41516867" target="_blank" rel="noreferrer noopener">B-세포 비호지킨 림프종</a>에 대한 CAR-NK 세포 치료제의 1상 임상 연구에서 첫 환자에게 투여했다고 발표한 후 49.86% 상승했다.
2. 스트라이드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>)의 주식은 회사가 1분기 실적이 예상보다 좋게 나타났고, 2025 회계연도 및 2분기 <a href="https://www.benzinga.com//node/41487340" target="_blank" rel="noreferrer noopener">매출 가이던스도 예상치를 상회</a>했다고 발표한 후 41.43% 급등했다. 애널리스트들이 <a href="https://www.benzinga.com/quote/lrn/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표</a>를 올렸다.
3. 퓨어사이클 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>)의 <a href="https://www.benzinga.com//node/41409452" target="_blank" rel="noreferrer noopener">주식은 32.21% 상승</a>했다.
4. 트럼프 미디어 앤 테크놀로지 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)의 주식은 지난주에 31.68% 상승했다. 이 주식은 다가오는 미국 선거를 앞두고 변동성을 보였다.
5. 지커 인텔리전트 테크놀러지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>)의 주식은 29.31% 상승했다. 여러 미국 상장 중국 주식들이 인민은행이 <a href="https://www.benzinga.com//node/41547149" target="_blank" rel="noreferrer noopener">7,000억 위안</a> (약 983억 6천만 달러)를 은행 시스템에 주입하고 금리를 2.0%로 유지했다고 발표한 후 상승했다.
6. 아이온큐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>)의 주식은 27.52% 상승했다.
7. 허크 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRI#NYSE">HRI</a>)의 주식은 회사가 3분기 매출 실적이 예상보다 좋았고 2024 회계연도 장비 <a href="https://www.benzinga.com//node/41455862" target="_blank" rel="noreferrer noopener">임대 매출 성장 전망을 상향 조정</a>했다고 발표한 후 21.76% 상승했다.
8. 테라울프(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>)의 주식은 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 가격 상승으로 18.59% 상승했다. 이 회사는 또한 4억 2,500만 달러를 전환사채로 조달할 것을 제안했다.
9. 아이리듬 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41462205" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">지오(Zio) AT 기기</a>의 이전 설계 변경과 관련된 510(k) 제출에 대해 FDA 승인을 받았다고 발표한 후 주가가 20.76% 상승했다.
10. 셀레스티카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>)의 주식은 회사가 3분기 실적이 예상보다 좋았고 4분기 매출 가이던스를 예상치를 상회한다고 발표한 후 19.99% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/41523564" target="_blank" rel="noreferrer noopener">주가 목표</a>를 올렸다.
또한 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ED%85%8C%EC%8A%AC%EB%9D%BC%EC%99%80-%EB%A6%AC-%EC%98%A4%ED%86%A0%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10%EA%B0%9C-%EB%8C%80/" target="_blank" rel="noopener">테슬라와 리 오토는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 21일-10월 25일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%A0%9C%EB%89%B4%EC%9D%B8-%ED%8C%8C%EC%B8%A0-%EB%B0%8F-%ED%83%91%EB%B9%8C%EB%93%9C%EA%B0%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%9D%B8-10/" target="_blank" rel="noopener">제뉴인 파츠 및 탑빌드가 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 21일-10월 25일)</a></li>
</ul>
Photo via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Herc Holdings

뉴스

에 대한 최신 뉴스 Herc Holdings (NYSE:HRI) 주식

월요일, 10월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌